Correlation Between Acumen Pharmaceuticals and Alto Neuroscience,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Acumen Pharmaceuticals and Alto Neuroscience, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acumen Pharmaceuticals and Alto Neuroscience, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Acumen Pharmaceuticals and Alto Neuroscience,, you can compare the effects of market volatilities on Acumen Pharmaceuticals and Alto Neuroscience, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acumen Pharmaceuticals with a short position of Alto Neuroscience,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acumen Pharmaceuticals and Alto Neuroscience,.

Diversification Opportunities for Acumen Pharmaceuticals and Alto Neuroscience,

0.56
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Acumen and Alto is 0.56. Overlapping area represents the amount of risk that can be diversified away by holding Acumen Pharmaceuticals and Alto Neuroscience, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alto Neuroscience, and Acumen Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acumen Pharmaceuticals are associated (or correlated) with Alto Neuroscience,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alto Neuroscience, has no effect on the direction of Acumen Pharmaceuticals i.e., Acumen Pharmaceuticals and Alto Neuroscience, go up and down completely randomly.

Pair Corralation between Acumen Pharmaceuticals and Alto Neuroscience,

Given the investment horizon of 90 days Acumen Pharmaceuticals is expected to generate 11.31 times less return on investment than Alto Neuroscience,. But when comparing it to its historical volatility, Acumen Pharmaceuticals is 2.3 times less risky than Alto Neuroscience,. It trades about 0.04 of its potential returns per unit of risk. Alto Neuroscience, is currently generating about 0.19 of returns per unit of risk over similar time horizon. If you would invest  394.00  in Alto Neuroscience, on August 25, 2025 and sell it today you would earn a total of  931.00  from holding Alto Neuroscience, or generate 236.29% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Acumen Pharmaceuticals  vs.  Alto Neuroscience,

 Performance 
       Timeline  
Acumen Pharmaceuticals 

Risk-Adjusted Performance

Soft

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Acumen Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Acumen Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.
Alto Neuroscience, 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Alto Neuroscience, are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Alto Neuroscience, displayed solid returns over the last few months and may actually be approaching a breakup point.

Acumen Pharmaceuticals and Alto Neuroscience, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Acumen Pharmaceuticals and Alto Neuroscience,

The main advantage of trading using opposite Acumen Pharmaceuticals and Alto Neuroscience, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acumen Pharmaceuticals position performs unexpectedly, Alto Neuroscience, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alto Neuroscience, will offset losses from the drop in Alto Neuroscience,'s long position.
The idea behind Acumen Pharmaceuticals and Alto Neuroscience, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Complementary Tools

Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance